| Citation: |
ZENG Zhimin, OUYANG Yuming, HE Jing, XIONG Shizhong, ZHONG Qiong. Sequential Thoracic Radiotherapy Improves Progression Free Survival of Patients with Extensive-disease Small Cell Lung Cancer, Compared with Consolidative Thoracic Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 209-213. DOI: 10.3971/j.issn.1000-8578.2017.03.011
|
To explore the effect of sequential thoracic radiotherapy on extensive-disease small cell lung cancer (ED-SCLC) compared with consolidative radiotherapy.
We collected 102 patients with ED-SCLC who received thoracic radiotherapy from January 2010 to June 2013. The progression free survival (PFS) and overall survival (OS) of two radiotherapy arms (sequential vs. consolidative radiotherapy) were analyzed by Kaplan-Meier curve method.
The median PFS and 1-year PFS rates were 11.0 month, and 39.6% in sequential thoracic radiotherapy group, 9.4 month and 4.6% in consolidative radiotherapy group (P=0.000). The median OS, 1-year and 2-year OS rates were 15.0m, 77.7% and 4.6% in sequential group, 14.2m, 82.4% and 2.4% in consolidative group (P=0.58). Univariate analysis showed that performance status (PS) score (=0), cycles of chemotherapy ( > 3) and sequential thoracic radiotherapy were significantly associated with better PFS (P=0.005) and multivariate analysis indicated that cycles of chemotherapy ( > 3) and sequential radiotherapy were independent favorable prognostic factors. Further, subgroup analysis showed that whether chemotherapy cycles > 3 or≤3, the PFS of patients who received sequential thoracic radiotherapy was longer.
Sequential thoracic radiotherapy could improved the PFS of some highly selective patients with ED-SCLC. Cycles of chemotherapy ( > 3) and sequential thoracic radiotherapy are two independent prognostic factors.
| [1] |
Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer[J]. Radiother Oncol, 2012, 102(2): 234-8. doi: 10.1016/j.radonc.2011.08.042
|
| [2] |
FrühM, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24 Suppl 6: vi99-105. https://www.researchgate.net/publication/291514099_Small-cell_lung_cancer_SCLC_ESMO_Clinical_Practice_Guidelines_for_diagnosis_treatment_and_follow-up
|
| [3] |
Byers LA, Rudin CM. Small cell lung cancer: where do we go from here?[J]. Cancer, 2015, 121(5): 664-72. doi: 10.1002/cncr.29098
|
| [4] |
NCCN guideline: Small Cell Lung Cancer, Version.5. 2015. Available at https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
|
| [5] |
Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer.[J]. N Engl J Med, 2007, 357(7): 664-72. doi: 10.1056/NEJMoa071780
|
| [6] |
Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis[J]. Cancer, 2011, 117(23): 5423-31. doi: 10.1002/cncr.v117.23
|
| [7] |
Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962): 36-42. doi: 10.1016/S0140-6736(14)61085-0
|
| [8] |
Amini A, Byers LA, Welsh JW, et al. Progress in the management of limited‐stage small cell lung cancer[J]. Cancer, 2014, 120(6): 790-8. doi: 10.1002/cncr.28505
|
| [9] |
Slotman BJ, Senan S. Radiotherapy in small-cell lung cancer: lessons learned and future directions[J]. Int J Radiat Oncol Biol Phys, 2011, 79(4): 998-1003. doi: 10.1016/j.ijrobp.2010.10.039
|
| [10] |
Kepka L, Baumann M. Radiotherapy in small cell lung cancer: Limited volumes in limited disease and adding thoracic radiotherapy in extended disease?[J]. Radiother Oncol, 2012, 102(2): 165-7. doi: 10.1016/j.radonc.2012.01.001
|
| [11] |
Videtic GM. The role of radiation therapy in small cell lung cancer[J]. Curr Oncol Rep, 2013, 15(4): 405-10. doi: 10.1007/s11912-013-0318-4
|
| [12] |
Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study[J]. J Clin Oncol, 1999, 17(7): 2092-9. doi: 10.1200/JCO.1999.17.7.2092
|
| [13] |
Giuliani ME, Atallah S, Sun A, et al. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy[J]. Clin Lung Cancer, 2011, 12(6): 375-9. doi: 10.1016/j.cllc.2011.03.028
|
| [14] |
Huber RM, Reck M, Thomas M. Current status and future strategies for multimodality treatment of unresectable stage Ⅲ nonsmallcell lung cancer[J]. Eur Respir J, 2013, 42(4): 1119-33. doi: 10.1183/09031936.00143112
|
| [15] |
Morabito A, Carillio G, Daniele G, et al. Treatment of small cell lung cancer[J]. Crit Rev Oncol Hematol, 2014, 91(3): 257-70. doi: 10.1016/j.critrevonc.2014.03.003
|
| [16] |
Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer[J]. Cancer Immunol Res, 2013, 1(6): 365-72. doi: 10.1158/2326-6066.CIR-13-0115
|
| [17] |
Lee KJ, Lee EJ, Hur GY, et al. The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer[J]. Korean J Intern Med, 2013, 28(4): 449-55. doi: 10.3904/kjim.2013.28.4.449
|
| [18] |
Sun JM, Ahn YC, Choi EK, et al. Phase Ⅲ trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer[J]. Ann Oncol, 2013, 24(8): 2088-92. doi: 10.1093/annonc/mdt140
|
| [19] |
Gore EM, Hu C, Sun A, et al. NRG Oncology/RTOG 0937: Randomized phase 2 study comparing prophylactic cranial irradiation (PCI) alone to PCI and consolidative extra-cranial irradiation for extensive disease small cell lung cancer (ED-SCLC)[J]. Int J Radiat Oncol Biol phys, 2016, 94(1): 5. https://www.researchgate.net/publication/286524380_NRG_OncologyRTOG_0937_Randomized_Phase_2_Study_Comparing_Prophylactic_Cranial_Irradiation_PCI_Alone_to_PCI_and_Consolidative_Extracranial_Irradiation_for_Extensive_Disease_Small_Cell_Lung_Cancer_ED-SC
|
| [1] | HU Lili, YIN Yanjun, ZHONG Wenjuan, QIU Feng. miR-200c Enhances Sensitivity of Lung Cancer Cell A549 to Paclitaxel and Gefitinib and Related Mechanism[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 760-764. DOI: 10.3971/j.issn.1000-8578.2015.08.003 |
| [2] | FAN Bei, LI Hongxia, WU Yumei, ZHAO Qun, DENG Xiaohong. Biological Characteristics of Paclitaxel-resistance Ovarian Cancer Cell Lines and Cryopreservation Methods[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 334-339. DOI: 10.3971/j.issn.1000-8578.2015.04.004 |
| [3] | QU Yuying, YUE Guijuan, LI Jiansheng, HUANG Hui. Effect of Jinlong Capsules on Reversing Paclitaxel-resistance Vincritine-resistance and Enhancing Sensitivity in Human Cancer Cell Lines[J]. Cancer Research on Prevention and Treatment, 2014, 41(08): 884-887. DOI: 10.3971/j.issn.1000-8578.2014.08.006 |
| [4] | ZHANG Jinlu, ZHANG Xiaohong, WANG Yurong, HE Chao, WU Jihui, LUO Cheng. MAGEA10 Expression in Human Lung Cancer A549 Cells Influenced by Viili Polysaccharides[J]. Cancer Research on Prevention and Treatment, 2013, 40(07): 635-638. DOI: 10.3971/j.issn.1000-8578.2013.07.002 |
| [5] | WU Jun, WEN Min, ZHANG Hai-tao. Galangin Induces Apoptosis on Lung Cancer A549 Cells[J]. Cancer Research on Prevention and Treatment, 2011, 38(11): 1228-1231. DOI: 10.3971/j.issn.1000-8578.2011.11.003 |
| [6] | DENG Chao, HE Yan, HU Chun-hong. Efficacy and Safety of Paclitaxel Liposomes in Treatment of 40 Patients with NSCLC[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 315-318. DOI: 10.3971/j.issn.1000-8578.2011.03.020 |
| [7] | XIAO Yu-jie, WANG Hong-mei, HAN Zheng-xiang, GAO Xiang-yang, PEI Dong-sheng, ZENG Ling-yu, DU Xiu-ping. Reverse Paclitaxel Resistance by Silencing stathmin and mdr1 in Ovarian Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 243-246. DOI: 10.3971/j.issn.1000-8578.2011.03.001 |
| [8] | LU Hong, FAN Qing-xia, WANG Rui-lin. Apoptosis in Paclitaxel Resistant Cell Line Ec9706/P-1 of Human Esophageal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(12): 1356-1359. DOI: 10.3971/j.issn.1000-8578.2010.12.006 |
| [9] | LI Ling, CHEN Fu-chun, CHEN Hong-lei, PAN Qi, DIAO Lu-ming. Effect of Combination of Docetaxel with Curcumin on Proliferation and Apoptosis of Human Lung Adenocarcinoma A549 Cell[J]. Cancer Research on Prevention and Treatment, 2010, 37(06): 617-620. DOI: 10.3971/j.issn.1000-8578.2010.06.003 |
| [10] | DONG Jun-hong, WANG Zhen-ming, FU Xin-hua, WANG Shou-xun, HUANG Huan-sheng. Effects of Silence survivin by RNAi on Apoptosis of A549 Cells and on Sensitivity of A549 Cells to Paclitaxel[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 266-268. DOI: 10.3971/j.issn.1000-8578.2010.03.006 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: